Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ipilimumab N01 + sintilimab + lenvatinib first-line therapy for advanced or metastatic TFE3-rearranged renal cell carcinoma
ChiCTR2600133947Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Sep 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ipilimumab, sintilimab and lenvatinib in renal cell carcinoma (RCC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
ipilimumabsintilimablenvatinib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on ChiCTR2600133947.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600133947.